Clinical Effect of Enrofloxacin in Dogs and Cats with Urinary Tract Infection

Abstract

Injectable and tablet formulations of enrofloxacin (ERFX), a fluorinated quinolone derivative, was administered to dogs and cats with urinary tract infections at a basic dose of 5mg/kg a day for 5 days in principle. Clinical signs, bacteruria and pyuria were improved in most cases including those without response to other antibiotics. The isolated bacteria were revealed to be highly susceptive to ERFX and resistant to commonly used drugs. Some local and gastrointestinal disorders were seen in injected and tablet cases, respectively, while not of importance.